126 related articles for article (PubMed ID: 24041229)
1. The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma.
Waters AM; Beierle EA
Anticancer Agents Med Chem; 2014 Jan; 14(1):46-51. PubMed ID: 24041229
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
He J; Gu L; Zhang H; Zhou M
Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
[TBL] [Abstract][Full Text] [Related]
3. MYCN, neuroblastoma and focal adhesion kinase (FAK).
Beierle EA
Front Biosci (Elite Ed); 2011 Jan; 3(2):421-33. PubMed ID: 21196322
[TBL] [Abstract][Full Text] [Related]
4. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M
Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861
[TBL] [Abstract][Full Text] [Related]
5. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
6. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
7. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.
Calao M; Sekyere EO; Cui HJ; Cheung BB; Thomas WD; Keating J; Chen JB; Raif A; Jankowski K; Davies NP; Bekkum MV; Chen B; Tan O; Ellis T; Norris MD; Haber M; Kim ES; Shohet JM; Trahair TN; Liu T; Wainwright BJ; Ding HF; Marshall GM
Oncogene; 2013 Aug; 32(31):3616-26. PubMed ID: 22907436
[TBL] [Abstract][Full Text] [Related]
8. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
9. Targeting the MYCN effector, FAK, in neuroblastoma.
Davidoff AM
Cell Cycle; 2010 Mar; 9(6):1026. PubMed ID: 20410685
[No Abstract] [Full Text] [Related]
10. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G
PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863
[TBL] [Abstract][Full Text] [Related]
11. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
[TBL] [Abstract][Full Text] [Related]
12. MDM2 as a critical effector of the MYCN oncogene in tumorigenesis.
Slack A; Shohet JM
Cell Cycle; 2005 Jul; 4(7):857-60. PubMed ID: 15917661
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
Beierle EA; Ma X; Stewart J; Nyberg C; Trujillo A; Cance WG; Golubovskaya VM
Cell Cycle; 2010 Mar; 9(5):1005-15. PubMed ID: 20160475
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
[TBL] [Abstract][Full Text] [Related]
15. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling.
Duffy DJ; Krstic A; Schwarzl T; Higgins DG; Kolch W
Mol Cancer Ther; 2014 Feb; 13(2):454-67. PubMed ID: 24282277
[TBL] [Abstract][Full Text] [Related]
16. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
[TBL] [Abstract][Full Text] [Related]
17. Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.
Yamaguchi Y; Takenobu H; Ohira M; Nakazawa A; Yoshida S; Akita N; Shimozato O; Iwama A; Nakagawara A; Kamijo T
Eur J Cancer; 2014 May; 50(8):1555-65. PubMed ID: 24559687
[TBL] [Abstract][Full Text] [Related]
18. MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival of tetraploid neuroblastoma cells.
Gogolin S; Batra R; Harder N; Ehemann V; Paffhausen T; Diessl N; Sagulenko V; Benner A; Gade S; Nolte I; Rohr K; König R; Westermann F
Cancer Lett; 2013 Apr; 331(1):35-45. PubMed ID: 23186832
[TBL] [Abstract][Full Text] [Related]
19. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
Slack A; Lozano G; Shohet JM
Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
[TBL] [Abstract][Full Text] [Related]
20. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells.
Gu L; Zhang H; He J; Li J; Huang M; Zhou M
Oncogene; 2012 Mar; 31(11):1342-53. PubMed ID: 21822304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
